Positron-Emission Tomography Clinical Trial
Official title:
68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease
As a new dual receptor (PSMA and FAP) targeting PET radiotracer, 68Ga-PSFA is promising as an excellent imaging agent applicable to PSMA/FAP positive diseases. In this research, we investigate the safety, biodistribution and potential usefulness of 68Ga-PSFA positron emission tomography (PET) for the diagnosis of lesions in PSMA/FAP positive diseases.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | December 31, 2026 |
Est. primary completion date | April 30, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. At least 18 years of age. 2. Signed informed consent. 3. Patients with suspected or newly diagnosed or previously malignant disease, with either PSMA or FAP positive expression (supporting evidence may include MRI, CT, and pathology report, etc). Exclusion Criteria: 1. Patients with non-malignant disease. 2. Patients with pregnancy. 3. The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent. 4. Known or expected hypersensitivity to 68Ga-PSFA or any of its components. 5. Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study. |
Country | Name | City | State |
---|---|---|---|
China | The First Affiliated Hospital of Chongqing Medical University | Chongqing | Chongqing |
Lead Sponsor | Collaborator |
---|---|
First Affiliated Hospital of Chongqing Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Diagnostic efficacy | The sensitivity, specificity, and accuracy of 68Ga-PSFA PET | 15 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04555642 -
Early Diagnosis of Therapy-associated Cardiotoxicity Basing on Multi-tracer Multimodality PET/MRI
|
||
Recruiting |
NCT05004961 -
The Performance of Multi-tracer Multimodality PET in Lymphoma
|
||
Recruiting |
NCT05188872 -
Application of 68Ga-Pentixafor PET/CT in Primary Aldosteronism and Pre-postoperative of SAAE
|
N/A | |
Recruiting |
NCT04983095 -
Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05610098 -
Gene Expression Profiles in Spinal Tuberculosis.
|
||
Recruiting |
NCT04416165 -
Comparison of FDG and FAPI in Patients With Various Types of Cancer
|
N/A | |
Recruiting |
NCT04750772 -
Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer
|
N/A | |
Recruiting |
NCT04831541 -
68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer
|
Early Phase 1 | |
Recruiting |
NCT06188468 -
ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Solid Tumors
|
N/A | |
Recruiting |
NCT06017973 -
The Role of Imaging in the Diagnosis, Management and Prognosis of Possible Non-convulsive Status Epilepticus
|
N/A | |
Recruiting |
NCT03830242 -
Diagnostic Significance of FDG PET/CT Dynamic Imaging in Detecting Metastatic Lymph Nodes With Papillary Thyroid Cancer.
|
N/A | |
Recruiting |
NCT05506566 -
68Ga-FAP-CHX PET/CT : Dosimetry and Preliminary Clinical Translational Studies
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04367948 -
Positron Nuclide Labeled NOTA-FAPI PET Study in Lymphoma
|
N/A | |
Recruiting |
NCT05757804 -
Study of 18F-0502B PET Imaging Targeting α-synuclein in the Diagnosis of α-synuclein-related Diseases
|
||
Completed |
NCT05392205 -
Comaprison of 68Ga-FAP-2286 and 18F-FDG PET/CT in Patients With Various Types of Cancer
|
N/A | |
Completed |
NCT03741231 -
18FDG-PET in Patients With Melanoma or NSCLC Treated With Immunotherapy
|
||
Completed |
NCT01035164 -
Evaluation of ZK 6032924 in Probable Alzheimer's Disease Patients Versus Healthy Volunteers and the Radiation Dosimetry of ZK 6032924 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03107663 -
⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma
|
Phase 1 | |
Recruiting |
NCT03636607 -
Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Primary Hepatocellular Carcinoma
|
N/A | |
Recruiting |
NCT06465017 -
ImmunoPET Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) in Thyroid Cancer
|
N/A |